LIFERIVER(SH:688317)2021-04-28 16:00Financial Performance - Operating revenue for the first quarter was RMB 656,230,414.60, a 201.37% increase compared to the same period last year[7] - Net profit attributable to shareholders increased by 221.52% year-on-year, amounting to RMB 316,215,504.78[7] - Basic earnings per share increased by 164.18% to RMB 1.77[7] - The company reported a total comprehensive income of ¥278.05 million for Q1 2021, compared to ¥62.08 million in Q1 2020, which is an increase of about 348%[29] - Operating profit for Q1 2021 reached ¥375.46 million, compared to ¥113.51 million in Q1 2020, indicating an increase of approximately 230%[28] - The company incurred a tax expense of ¥58.42 million in Q1 2021, compared to ¥15.15 million in Q1 2020, which is an increase of approximately 285%[28] Assets and Liabilities - Total assets increased by 122.09% year-on-year, reaching RMB 4,174,307,922.64[7] - The company's total assets as of March 31, 2021, amounted to RMB 3,686,735,980.88, up from RMB 1,582,916,525.82 at the end of the previous year[19] - Total liabilities decreased to ¥574,686,167.33 in Q1 2021 from ¥596,398,384.73 in Q4 2020, reflecting a reduction of approximately 3.7%[25] - The company's equity increased to ¥3,649,959,197.74 in Q1 2021, up from ¥1,438,570,779.29 in Q4 2020, marking an increase of around 153.5%[25] Cash Flow - Cash flow from operating activities rose by 29.88% to RMB 179,287,670.20[7] - The net cash flow from operating activities was ¥179,287,670.20, up from ¥138,044,205.22 in the same period last year, reflecting a growth of 29.8%[32] - The company reported cash inflow from operating activities of ¥635,207,144.40, a significant increase of 184.1% compared to ¥224,026,524.37 in Q1 2020[32] - Total cash inflow from financing activities reached ¥1,958,830,045.24, with no inflow recorded in Q1 2020[33] - The net cash flow from financing activities was ¥1,948,049,340.89, compared to no cash outflow in the previous year[33] - The company reported a net cash outflow from investing activities of ¥244,979,043.85, compared to ¥7,083,378.88 in Q1 2020, reflecting an increase of 3,457.5%[33] Research and Development - Research and development expenses accounted for 2.37% of operating revenue, down from 3.17%[8] - Research and development expenses rose by 125.57% to RMB 15,580,686.48, indicating the company's commitment to innovation and technology development[15] - Research and development expenses for Q1 2021 totaled ¥15.58 million, compared to ¥6.91 million in Q1 2020, marking an increase of approximately 125%[28] Shareholder Information - The top shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 33.37% of the shares[11] - The total number of shareholders at the end of the reporting period was not specified[9] Inventory and Operating Costs - The total inventory increased by 122.91% to RMB 293,631,918.12, attributed to increased stockpiling due to the ongoing COVID-19 pandemic[15] - The company's gross profit margin increased, with operating costs rising by 303.95% to RMB 182,927,434.73, reflecting the revenue growth[15] - The total operating costs for Q1 2021 were ¥276.84 million, up from ¥101.10 million in Q1 2020, indicating a rise of about 174%[28] Future Outlook - The company has not indicated any significant changes in its future outlook or guidance for the upcoming periods[16]